Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great post, Alinea, reminding us that there are people calling the shorts out.
Now if only NY AG Schneiderman (who is the only public official that seems interested in the rule of securities laws) would take up the matter the article addresses, using some of the logic used to go after DraftKings and FanDuel,
The attorney general’s office also said that ads on the two sites “seriously mislead New York citizens about their prospects of winning.” State investigators found that to date, “the top 1 percent of DraftKings winners receive the vast majority of the winnings.”
Here is a link to CNN; it might not be the only way to contact them.
http://www.cnn.com/feedback/
WW, I interpret the Week 5 to be the end point of the P2A portion of the study, i.e., the 36 days, and not an interim time period in the P2B study.
I apologize if I'm off base, but I was out this PM and missed the last 400+ posts.
I believe the reason this data is not being released before the conference by Anavex is that the data is not directly theirs ... it is Professor McFarlane's and until he releases it, Anavex can only sit and wait for the public disclosure to which it can then respond.
Hopefully, press conference or conference call will be forthcoming shortly after release with the good Doctor commenting on said data.
I sent an email last week asking if there would be a conference call with the good Doctor, but have not heard back.
Has anyone heard if there will be call/press conference or not?
Flying A, did he share with you his opinion of the good Doctor?
What have you been smoking or drinking or both? Hope you are looking to win cheaper shares versus stupidity that AVXL will tank. Do you have any analysis backing your vacuum?
Of course, you could be right ... NOT!
PBS News Hour did a piece on AD last night. One point noted was the cost of AD care in 2014 was $224 Billion. THis did not include care given by family members, and out-of-pocket costs they expend, e.g., to transport their loved one.
With all the posts over the last few days, I missed the post, tootall, you allude to in 2nd ¶. If you could enlighten me, I'd appreciate it.
Also, as you noted the market size is enormous for those with AD, but what would the market size be if AVXL has the drug to AVOID AD for life, besides the one for those that do?
10 days to go for Barcelona release.
With data to be released on the 7th, do we know what the range of expectations is, what will be considered below expectations or above? Is the expectation bar set at the results released on July 22nd?
With the expansion of the time frame from 26 weeks to 52 weeks, we have high hopes for the data, but who determines the expectations and what are the numbers, acceptable side effects, etc.?
Yes, Star was/is still disappointing because Anatabloc worked for me to clear up an arthritic foot. Might have been the cause FDA issues ... it cured ailments and therefore, was a drug, not a supplement. Plus Jonnie was a distraction and wasted lots of $$$.
He hit some homers (Medarex and I disliked the BMS deal) and whiffed even more, but that is investing in biotechs.
For the record, it is Lincoln Park as in the old Steve Goodman song, "Lincoln Park Pirates."
Tom, remember Cox was also the guy who suggested Anavex and depending when people bought, they are looking better with that company today than 2 years ago. [I believe you follow AVXL.]
ISCO might be the same, especially if they would bring in someone like Dr. Missling to run the show.
Yes, I am in both and an early investor, too, based on Patrick's recommendations.
Raja, this is my morning song beginning November 8, 2015 with Dr. Missling as Sly.
Taunis, our heart-felt prayers go out to you and others who are facing the effects these diseases are causing to loved ones. Our family lost a wonderful aunt to AD back in the late 80's, early in the recognition period of how devastating a disease it is.
For those on this MB who have experienced AD's impact, I believe our first wish is not financial gain, but that Anavex's products are successful so fewer people in the future will go through what we have and the disease will be halted and reversed for those victims and, God willing, eradicated.
I visit several living-assisted and memory care facilities each week with the Holy Eucharist and am humble each time as I see the devastation AD has caused and the hurt in the eyes of those suffering while family members agonize over the financial commitments needed to care for their loved ones with no hope of bringing that person back.
I pray Anavex's science wins out over Alzheimer's and the other mind distorting diseases for your sake and mine and all those touched by them.
May the Lord bless and give you strength.
CI, did you see this?
Profits up, Biogen cuts 11% of global workforce
by Erika Fry @ErikaFry OCTOBER 21, 2015, 3:24 PM EDT
E-mail Tweet Facebook Linkedin
Share icons
The big biotech announces restructuring and sales growth
Earlier this year, Biogen BIIB 0.06% was the hottest biotech in the business. Today, the company announced it will cut 11% of its global workforce—some 880 employees—and shutter a number of pipeline programs by the end of the year. The Cambridge-based biotech announced its corporate restructuring plans Wednesday morning in an otherwise rosy third quarter earnings report, in which the company beat sales estimates and raised earnings guidance for the year. Revenues were up 11% for the quarter. Profits rose 13%.
CEO George Scangos called the workforce reduction an “extremely difficult” but necessary decision to fulfill the company’s goals. Biogen plans to reinvest the projected $250 million in savings into commercial initiatives—largely the marketing of Tecfidera, the company’s blockbuster multiple sclerosis medication, whose sales disappointed last quarter. Biogen’s stock dropped 22% in July after the company reported lower-than-expected demand for the drug. Biogen is actively working to reverse that with a television advertising campaign and increased sales calls to physicians. It also recently announced the departure of its head of global commercial operations, Tony Kingsley.
Savings will also go to focus on pipeline opportunities. The company has a number of promising drugs in mid- and late-stage development, perhaps most notably aducanumab, a promising medication for early-stage Alzheimer’s patients. Data released in March from early clinical testing of the drug sent Biogen’s stock price soaring to an all-time of high of $480—it is now around $270, partly due to the downdraft in biotech stocks—and was met by unusual levels of enthusiasm from the Alzheimer’s research community. Biogen has begun to enroll patients in a late-stage trial of aducanumab, which Fortune wrote about in April and is the first-ever to both appear to significantly remove the brain plaques associated with Alzheimer’s and to slow cognitive decline in patients.
The biotech expects to take a $85-95 million charge next quarter as a result of the restructuring. Among the drug development programs Biogen will discontinue are some of those focused on MS and other immunological diseases.
Biogen may be cooling, but it is hardly struggling. The company expects revenue and profit to continue to grow with increasing patients and cost control measures. Through midday trading, Biogen’s stock was up 2%.
NYC, how did you know on Wednesday that Thursday was going to be "bumpy," (which it was)?
Can anyone explain why the improvement drops from 7 to 5.5 the longer people are on the combination? Does it happen because donepezil's impact does decline over time (I believe I read that the impact is minimal after 18 months)?
[/quote]The findings in a humanized calibrated realistic cortical network computer model of Alzheimer’s disease predict that combining ANAVEX 2-73 with low dose (5mg) donepezil (Aricept®) will show up to 7 points improvement in Alzheimer’s Disease Assessment Scale–Cognitive (“ADAS-Cog”) at 12 weeks and up to 5.5 points at 26 weeks in mild-to-moderate Alzheimer’s patients, respectively. [/quote]
Once again, George, you are on point. The deterioration in AD patients is well documented and there is no need to have control groups or people receiving placebo since it is known what will be the end result for those folks, regardless of the time.
Listening to PBS NewsHour piece about autism and hope Anavex has a solution for the 1 in 68 kids that have this ailment in the near term ... almost as bad as AD since it is a lifetime problem.
The one you cited in Post #25004.
If he had, which I don't believe he has, then he and Anavex will have the SEC all over them for disclosure of material information to a select group of people, and is to the determent of existing shareholders. He needs to be extremely careful as to what he says until that data is released publicly.
That rule applies to lawyers, investment bankers and others involved in any planned offering.
Tootall, that is a nice synopsis of the market potential and is very true.
As NYC states, IF the science is proven with minimal side effects (remember Vioxx, the FDA does), then investors will be dizzy looking up as the moon comes into view. But, it is a Big "IF."
The Impressions' "Amen" with a Christmas regerence. May AVXL be our Christmas present to our families!
http://secondhandsongs.com/performance/123896/versions
Outstanding shares are used; not all authorized shares have been issued.
we can see real jump in SP on Nov 7th
Yesterday PM, I felt betrayed; today enlightened about the R/S. The good Doctor did not want to leave the institutional investors at the starting gate; this allows them to get in before the big news hits in November.
We have had anecdotal info as to the full enrollment and the Barcelona presentation days/weeks before the Company released a PR, allowing us to buy ahead of the news. Thank you who have done the DD to bring that to us.
Now, let the big guys in and try to find shares.
None of those items should pose any problems given that a new fiscal year began last week. This (new fiscal year) may have been the reason for the R/S now.
IMO - The SOX documentation should not take long since it is a small office of less than 10 people. In my experience, it is a massive project when you have hundreds or thousands of employees and many departments.
All warrants will be adjusted to a post R/S basis, i.e., warrants for 1,000 shares will now be for 250.
AVXL did this so hastily that no one proof-read it.
I hope the good Doctor understands he is not getting a million shares for the uplisting on a post R/S basis.
No problem, circa. The potential of AVXL and its current position might allow it to exceed PCYC's market cap at the end. The key to me is: will the science prove out in the long run?
I'm willing to wait six years as long as the s/holders are not short changed. I think Dr. M understands the enormous potential if the science is proven.
Minotaur and maskone, if AVXL has the goods with its various drugs to be as revolutionary as the early indication are and on a long term basis does not wane in its effectiveness nor cause any harm, it will be the 21st century equivalent to penicillin was in the 19th century.
The impact is tremendous in the savings in medical and health costs and the indirect savings for families, caretakers, etc. ... it will be huge. Every American over 55 should have 1,000 shares or more so s/he will be able to pay for all the dinners, dancing, traveling that they will do as independent and active citizens rather than sitting watching TV with other semi-comatose people if there were NO AVXL drugs to save them.
Followers of AVXL, don't think about Acadia as eetrade highlights ... think PCYC that went from 90 cents in 2009 to ~$260 when it was bought this year ... and NO R/S!
If the science proves out long-term (not like te withdrawn Vioxx) and Dr. M is as good as we give him credit for, the M's are replaced by B's! AVXL will be > $100B+++ in the long run if the science is right, because it addresses and stops the causes of AD, Epilepsy, PD, et al!
What was your question to IR?
Great find with "Late Breaking Communication" that signals something big is going to happen that required this type of listing.
It is good the Australian Cogstate guy, Paul Maruff, is coming, too.
Observation - Something strange with this agenda, though ... Why is this shown down the horizontal side on some pages:
"CTAD Philadelphia 2015 Program" as Philly was the site of the 2014 conference.
Thank you, George, and LJ.
My wife was looking up Anavex's competition and did not find very much on Treventis, other than what the two of you addressed. I asked to find out if there was any more info in the public domain than that.
I appreciate the help.
Does anyone know how Treventis is progressing, when compared to Anavex? It appears it is taking the same approach as Anavex, focusing on the folding of proteins.
Tootall, I think Dr. MacFarland added 11 between the July 22 PR and the end of August when the Down Under poster was told the enrollment was full. Here's my logic:
Dr. M. said on July 22 that the trial was 2/3 full, which means 21 people (of 32) with 12 included in the those first results. That left 9 in the 36 day window.
Thereafter, I believe caregivers, having heard the improvement being reported, probably rushed to get their family member/patient one of the 11 remaining slots.
With the movie "Concussion" and other articles on CTE findings, is one of Anavex's products, e.g., Anavex Plus, a potential product for NFL, colleges and all who play football? Could a trial be set-up for this without FDA involvement or under a fast track basis?
It appears to be for period ended March 2014 which does not make sense that it is a current filing. Not traditional in format of an SEC filing.
Reference is made in tab of "XBRL" ... ?
No mention on Edgar of a filing with SEC.
Maybe, it is a misfiling by someone.
That is true about the speculation, which was based on an inference that the site claiming it was fully enrolled would have suggested another site if there were spots still opened elsewhere. Researcher, Dr. MacFarland, would have asked that a referral to another site be done.
Also, I believe others have posted that the trial was fully enrolled by late August.